Atara Biotherapeutics Announces First Clinical Data from Ong

Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported StudiesCompletion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commission Approval On-Track for Q4 2022SOUTH SAN...

Related Keywords

Germany , Mccormick Place , Illinois , United States , California , South San Francisco , Thousand Oaks , Chicago , American , Eric Hyllengren , Ralf Trappe , Jakob Dupont , Atara Biotherapeutics Inc , American Society Of Clinical Oncology , Linkedin , Twitter , Mccormick Place Convention Center Chicago , European Commission , European Commission Approval , Nasdaq , Head Of Global Research Development At Atara , Exchange Commission , European Medicines Agency , Securities Exchange , Access Program , Overall Response Rate , Previously Reported , All Pre Approval Inspections Required , Authorization Application , Anticipated European Commission Approval On Track , Expanded Access Program , Clinical Oncology , Annual Meeting , Global Research , Marketing Authorization Application , Good Manufacturing Practice , Diakonie Krankenhaus Bremen , Hematologic Malignancies , Chronic Lymphocytic Leukemia , Securities Act , Securities Exchange Act , Southern California , Financial Condition ,